Back to News
Market Impact: 0.25
Palvella Completes Rolling NDA For QTORIN Rapamycin In Microcystic Lymphatic Malformatios
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
Palvella Therapeutics (PVLA) completed the rolling NDA submission to the U.S. FDA for QTORIN 3.9% rapamycin anhydrous gel. The milestone is a positive regulatory progression toward potential review, though it does not itself confirm approval or timelines.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
PVLA0.45
More News
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- Penske Automotive agrees to be taken private by Penske, Mitsui
- Faraday Copper completes acquisition of BHP’s San Manuel project
- Supermicro promised a new CFO in December 2024. A $2.5 billion smuggling case and a co-founder’s arrest later, it has one
- Blackstone President Jon Gray Bets Big on AI Boom
- What's behind the sell-off in AI neocloud stocks like CoreWeave and Nebius